For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  CJC-1295 Without DAC
Performance & Musclepreclinical

CJC-1295 Without DAC

Mod GRF 1-29
Performance & Muscle · CAS 863288-34-0
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Performance & Muscle
Evidence grade
D
PubMed records
5
Female-tagged
1
Sex-analysis
0
CAS
863288-34-0
D
Evidence grade D, Preclinical / animal evidence only across 5 indexed studies. No human trial data. How grades work →
Female evidence: None
CJC-1295 Without DAC: of 5 PubMed records, 1 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-17. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

CJC-1295 without DAC, also known as Modified GRF (1-29), is a synthetic 29-amino-acid analogue of growth-hormone-releasing hormone (GHRH). Lacking the albumin-binding Drug Affinity Complex of its longer-acting counterpart, it carries a much shorter duration of action, which gives it a research-friendly profile for probing brief, time-resolved receptor events.

In endocrine and secretagogue research models, this analogue has been studied as a GHRH-receptor agonist, particularly for the acute and pulsatile stimulation of growth-hormone release. Its rapid clearance makes it a useful research material for investigators who want to characterize the immediate, transient phase of GHRH signaling rather than the sustained activation associated with DAC-modified versions.

Human data on this compound is minimal and has not been analyzed by sex, so its place in a catalog rests on its value as a mechanistic tool. Whether the studied pathways translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women. Supplied for in-vitro and laboratory research only.

Summary

CJC-1295 without DAC (Modified GRF 1-29) is a short-acting growth-hormone-releasing hormone analog used as a tool compound in secretagogue research. Human data is minimal and not analyzed by sex.

Evidence in women

Menstrual cycle
Unstudied
No menstrual cycle interaction data.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data.
Hormonal interactions
Unstudied
The GH axis interacts with estrogen generally, but no study characterizes this for this compound in women.
Perimenopause & menopause
Unstudied
No data in perimenopausal or menopausal populations.
Sex differences
Unstudied
In the indexed literature, many studies included female subjects and none reported sex-stratified outcomes.

Mechanism

A GHRH-receptor agonist studied for acute, pulsatile stimulation of growth-hormone release in endocrine research models.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Reported in research contexts only; no established human dose.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: active malignancy (theoretical)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

injection-site reactionstransient flushingwater retention

CJC-1295 Without DAC reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for CJC-1295 Without DAC

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from CJC-1295 Without DAC's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is CJC-1295 Without DAC?

CJC-1295 Without DAC, also known as Mod GRF 1-29, is a research compound in our performance muscle category. CJC-1295 without DAC (Modified GRF 1-29) is a short-acting growth-hormone-releasing hormone analog used as a tool compound in secretagogue research.

Is CJC-1295 Without DAC studied in women?

CJC-1295 Without DAC: of 5 PubMed records, 1 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this none: no PubMed record for CJC-1295 Without DAC is tagged as including female subjects, so its effects in women are effectively unstudied. That blank is the finding, not a safety signal, and we do not fill it with guesses.

Has CJC-1295 Without DAC been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does CJC-1295 Without DAC have, and why?

CJC-1295 Without DAC carries evidence grade D. Preclinical / animal evidence only across 5 indexed studies. No human trial data.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for CJC-1295 Without DAC?

No. A female-specific dose for CJC-1295 Without DAC is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is CJC-1295 Without DAC administered in research?

In the published literature, CJC-1295 Without DAC is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for CJC-1295 Without DAC?

Effects reported in the research literature include injection-site reactions, transient flushing, water retention. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for CJC-1295 Without DAC?

The CAS registry number for CJC-1295 Without DAC is 863288-34-0. It is also referred to as Mod GRF 1-29, modified GRF (1-29). Use it to confirm identity against a Certificate of Analysis.

How should CJC-1295 Without DAC be stored and handled?

CJC-1295 Without DAC sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy CJC-1295 Without DAC for research?

For laboratory research use, CJC-1295 Without DAC is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy CJC-1295 Without DAC at Aurevena Research
Research-use supplier: CJC-1295 Without DAC is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Related peptides

2X Blend CJC-1295 WO DAC (5mg) / Ipamorelin·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
ACE-031C
ACE-031: of 48 PubMed records, 11 are tagged as including female subjects and 0 carry a sex-analysis tag.
AICARB
AICAR: of 2,496 PubMed records, 329 are tagged as including female subjects and 2 carry a sex-analysis tag.
CJC-1295 with DACC
CJC-1295 with DAC: of 32 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.